Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

408 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Use of a "critical difference" statistical criterion improves the predictive utility of the Health Assessment Questionnaire-Disability Index score in patients with rheumatoid arthritis.
Behrens F, Koehm M, Schwaneck EC, Schmalzing M, Gnann H, Greger G, Tony HP, Burkhardt H. Behrens F, et al. Among authors: burkhardt h. BMC Rheumatol. 2019 Dec 10;3:51. doi: 10.1186/s41927-019-0095-2. eCollection 2019. BMC Rheumatol. 2019. PMID: 31867564 Free PMC article.
Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis.
Buch MH, Smolen JS, Betteridge N, Breedveld FC, Burmester G, Dörner T, Ferraccioli G, Gottenberg JE, Isaacs J, Kvien TK, Mariette X, Martin-Mola E, Pavelka K, Tak PP, van der Heijde D, van Vollenhoven RF, Emery P; Rituximab Consensus Expert Committee. Buch MH, et al. Ann Rheum Dis. 2011 Jun;70(6):909-20. doi: 10.1136/ard.2010.144998. Epub 2011 Mar 6. Ann Rheum Dis. 2011. PMID: 21378402 Free PMC article.
German guidelines for the sequential medical treatment of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs.
Albrecht K, Krüger K, Wollenhaupt J, Alten R, Backhaus M, Baerwald C, Bolten W, Braun J, Burkhardt H, Burmester GR, Gaubitz M, Gause A, Gromnica-Ihle E, Kellner H, Kuipers J, Krause A, Lorenz HM, Manger B, Nüßlein H, Pott HG, Rubbert-Roth A, Schneider M, Specker C, Schulze-Koops H, Tony HP, Wassenberg S, Müller-Ladner U; German Society of Rheumatology. Albrecht K, et al. Among authors: burkhardt h. Rheumatol Int. 2014 Jan;34(1):1-9. doi: 10.1007/s00296-013-2848-3. Epub 2013 Aug 14. Rheumatol Int. 2014. PMID: 23942828 Review.
MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial.
Behrens F, Tak PP, Østergaard M, Stoilov R, Wiland P, Huizinga TW, Berenfus VY, Vladeva S, Rech J, Rubbert-Roth A, Korkosz M, Rekalov D, Zupanets IA, Ejbjerg BJ, Geiseler J, Fresenius J, Korolkiewicz RP, Schottelius AJ, Burkhardt H. Behrens F, et al. Among authors: burkhardt h. Ann Rheum Dis. 2015 Jun;74(6):1058-64. doi: 10.1136/annrheumdis-2013-204816. Epub 2014 Feb 17. Ann Rheum Dis. 2015. PMID: 24534756 Free PMC article. Clinical Trial.
PTPN22 is associated with susceptibility to psoriatic arthritis but not psoriasis: evidence for a further PsA-specific risk locus.
Bowes J, Loehr S, Budu-Aggrey A, Uebe S, Bruce IN, Feletar M, Marzo-Ortega H, Helliwell P, Ryan AW, Kane D, Korendowych E, Alenius GM, Giardina E, Packham J, McManus R, FitzGerald O, Brown MA, Behrens F, Burkhardt H, McHugh N, Huffmeier U, Ho P, Reis A, Barton A. Bowes J, et al. Among authors: burkhardt h. Ann Rheum Dis. 2015 Oct;74(10):1882-5. doi: 10.1136/annrheumdis-2014-207187. Epub 2015 Apr 28. Ann Rheum Dis. 2015. PMID: 25923216 Free PMC article.
408 results